Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications

Emma Boretti, Jean-Michel Dogné, Jonathan Douxfils

Open source

DOI: 10.1210/jendso/bvag082
Published: 2026-04-01
Container: Journal of the Endocrine Society
Publisher: The Endocrine Society
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1210/jendso/bvag082,
  title = {Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications},
  author = {Emma Boretti and Jean-Michel Dogné and Jonathan Douxfils},
  year = {2026},
  journal = {Journal of the Endocrine Society},
  doi = {10.1210/jendso/bvag082},
  url = {https://doi.org/10.1210/jendso/bvag082}
}

RIS

TY  - JOUR
TI  - Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications
AU  - Emma Boretti
AU  - Jean-Michel Dogné
AU  - Jonathan Douxfils
PY  - 2026
JO  - Journal of the Endocrine Society
DO  - 10.1210/jendso/bvag082
UR  - https://doi.org/10.1210/jendso/bvag082
ER  -

APA

Boretti, E., Dogné, J., & Douxfils, J. (2026). Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications. Journal of the Endocrine Society. https://doi.org/10.1210/jendso/bvag082

Source records

crossref · retrieved 2026-09-25T09:20:07.759Z